Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment... April 27, 2026 Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological... July 16, 2021 Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... April 13, 2021 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Load more HOT NEWS Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with... How to Clean Your Home When Caring for Someone With Cancer Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,... Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney
